EVALUATION OF EFFICACY AND SAFETY OF ORAL VITAMIN D3 AND VITAMIN E AS AN ADD-ON-THERAPY TO METHOTREXATE IN PATIENTS OF MODERATE CHRONIC PLAQUE PSORIASIS
DOI:
https://doi.org/10.22159/ajpcr.2023.v16i10.48066Keywords:
moderate chronic plaque psoriasis, methotrexate, Psoriasis area and severity index, Dermatology and life quality index, Psoriasis disability indexAbstract
Objective: This study was conducted with the aim to evaluate the efficacy and safety of oral Vitamin D3 and Vitamin E as an add-on-therapy to methotrexate (MTX) in patients of moderate chronic plaque psoriasis.
Methods: In this prospective, open-labeled, randomized, and comparative clinical study, a total of 120 patients of age 20–60 years with moderate chronic plaque psoriasis attending the dermatology outpatient department were randomly allocated into three groups of 40 each, i.e., Group M, Group D, and Group E. Group M received MTX (7.5 mg) tablet orally weekly, Group D received MTX (7.5 mg) and Vitamin D3 (60,000 IU) sachet orally weekly, and Group E received MTX (7.5 mg) weekly and Vitamin E (400 mg) daily. Efficacy assessment was done through the following primary parameters-psoriasis area and severity index (PASI) score, dermatology life quality index (DLQI), and psoriasis disability index (PDI), and secondary parameters such as Vitamin D deficiency and insufficiency among the study participants and improvement of serum 25(OH)D concentration. Adverse events were monitored.
Results: PASI and DLQI were calculated at the time of recruitment (baseline), 1 month, 2 months, 3 months, and 4 months, and PDI and serum Vitamin D were calculated at baseline and 4 months. On intergroup comparison of PASI score and PDI, statistically significant results were seen at 4 months. DLQI showed significant results at 2, 3, and 4 months. Significant results were found in Group D which signifies improvement in serum Vitamin D levels. Mild side effects were seen at the end of 4 months.
Conclusion: The present study suggested that Vitamin D as an add-on therapy was found to cause a significant reduction in psoriatic lesions. It could be a promising drug in patients with psoriasis to improve the psoriatic lesions, when combined can reduce the dose of MTX, thereby minimizing the side effects.
Downloads
References
Di Meglio PD, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med 2014;4:1-30. doi: 10.1101/cshperspect.a015354, PMID 25085957
Adiguna MS, Rusyati LM, Sudarsa PS. Correlation of plasma Vitamin D receptors with the severity of psoriasis vulgaris. Bali Med J 2020;9:668-71. doi: 10.15562/bmj.v9i3.2013
Kim WB, Jeurome D, Yeung J. Diagnosis and management of psoriasis. Cam Fam Phys 2017;63:278-85.
Czarnecka-Operacz M, Sadowska-Przytocka A. The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge. Postepy Dermatol Alergol 2014;31:392-400. doi: 10.5114/ pdia.2014.47121, PMID 25610355
Usedom E, Neidig L, Allen HB. Psoriasis and fat-soluble vitamins: A review. J Clin Exp Dermatol Res 2017;8:421. doi: 10.4172/2155-9554.1000421
Soleymani T, Hung T, Soung J. The role of Vitamin D in psoriasis: A review. Int J Dermatol 2015;54:383-92. doi: 10.1111/ijd.12790, PMID 25601579
Liluashvili S, Kituashvili T. Dermatology life quality index and disease coping strategies in psoriasis patients. Postepy Dermatol Alergol 2019;36:419-24. doi: 10.5114/ada.2018.75810, PMID 31616215
Mir AA, Chattopadhyay A, Pramanick J, Gautam A, Mir SA, Koley M, et al. Psychometric validation of the psoriasis disability index questionnaire (translated Bengali version): A cross-sectional study. J Dermatol Dermatol Surg 2020;24:25-32. doi: 10.4103/jdds. jdds_38_19
Coates LC, Merola JF, Grieb SM, Mease PJ, Duffin KC. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl 2020;96:31-5. doi: 10.3899/jrheum.200124, PMID 32482765
Yan K, Zhang Y, Han L, Huang Q, Zhang Z, Fang X, et al. Safety and efficacy of methotrexate for Chinese adults with psoriasis with and without psoriatic arthritis. JAMA Dermatol 2019;155:327-34. doi: 10.1001/jamadermatol.2018.5194, PMID 30698628
Chung M, Bartholomew E, Yeroushalmi S, Hakimi M, Bhutani T, Liao W. Dietary intervention and supplements in the management of psoriasis: Current perspectives. Psoriasis (Auckl) 2022;12:151-76. doi: 10.2147/PTT.S328581, PMID 35769285
Keen MA, Hassan I. Vitamin E in dermatology. Indian Dermatol Online J 2016;7:311-5. doi: 10.4103/2229-5178.185494, PMID 27559512
De Jong EM, Mørk NJ, Seijger MM, De La Brassine M, Lauharanta J, Jansen CT, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: Results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003;148:318-25. doi: 10.1046/j.1365-2133.2003.05173.x, PMID 12588386
Disphanurat W, Viarasilpa W, Chakkavillumrong P, Pongcharoen P. The clinical effect of oral Vitamin D2 supplementation on psoriasis: A double-blind, randomized, placebo-controlled study. Dermatol Res Pract 2019;2019:5237642.
Prtina A, Grabež M, Vujnić M, Rašeta-Simović N. The role of high-dose Vitamin D supplementation on disease severity and lipid profile in psoriatic patients-a pilot study. Scr Med 2020;51:141-6. doi: 10.5937/ scriptamed51-28287
Hassan R, Kallan F, Subramanian S, Pillai RT, Dinachandran A. Vitamin D deficiency in psoriatic patients-a case control study. IP Indian J Clin Exp Dermatol 2019;5:37-40. doi: 10.18231/2581- 4729.2019.0009
Published
How to Cite
Issue
Section
Copyright (c) 2023 Garima Narang Guddu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.
